Symbols

GOSS

Gossamer Bio·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 0

Stock Price Surged Significantly

Ample Liquidity

High Gross Profit Margin

RSI Oversold

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GOSS

Gossamer Bio, Inc.

A clinical-stage biopharmaceutical company that developing therapeutics in the disease areas of immunology, inflammation and oncology

Industry

Biological Technology

Established Date

10/26/2015

Listing Date

02/08/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

161

Fiscal Year Ends

12-31

Website

www.gossamerbio.com

Security Type

Common stock

Office address

3115 Merryfield Row, Suite 120, San Diego, California 92121

Business

Introduction

Gossamer Bio, Inc., was incorporated under the laws of the State of Delaware on October 26, 2015. The Company is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, including pulmonary hypertension and pulmonary hypertension associated with interstitial lung disease. It is led by a management team with extensive experience in leading biopharmaceutical companies.

Company Financials

EPS

GOSS has released its 2025 Q4 earnings. EPS was reported at -0.21, versus the expected -0.19, missing expectations. The chart below visualizes how GOSS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

GOSS has released its 2025 Q4 earnings report, with revenue of 13.80M, reflecting a YoY change of 47.13%, and net profit of -47.24M, showing a YoY change of -43.02%. The Sankey diagram below clearly presents GOSS's revenue sources and cost distribution.